During Friday’s current trade, Constellium NV (NYSE:CSTM)’s shares incline 1.26% to $12.03.
Constellium NV (CSTM) was aboard Orion’s successful first flight test, Exploration Flight Test-1 (EFT-1). Built by Lockheed Martin, NASA’s Orion spacecraft is designed for human exploration of deep space.
In 2010, after a two-year materials study by Lockheed Martin – AIRWARE® 2195 and 2050 low density alloys manufactured at Constellium’s facilities located in Ravenswood, West Virginia, USA and Montreuil-Juigne and Issoire, France, – were chosen as key structural materials of the Orion spacecraft based on their proven reliability and safety in space in the study.
The alloys’ inherent low density, high-specific stiffness, strength and excellent mechanical properties ensure material high-performance characteristics during demanding launch and landing phases, and at the same time, a lower density to facilitate the ascent to outer space, contributing to a successful EFT-1.
Constellium N.V. is engaged in the design, manufacture, and sale of specialty rolled and extruded aluminum products for the aerospace, packaging, and automotive end-markets. The company operates in three segments: Aerospace & Transportation, Packaging & Automotive Rolled Products, and Automotive Structures & Industry.
Biogen Inc (NASDAQ:BIIB)‘s shares gain 1.77% to $408.65, during the current trading session Friday’s, hitting its highest level.
A chronic disease like relapsing MS (RMS) can complicate common aspects of everyday life, and a new program from Biogen (BIIB) and SELF is helping women navigate these familiar issues. Reimagine MySelf, which is now available on SELF.com, provides women access to editorial content and an exclusive blog series where writers from the SELF Made Blogger Collective and experts offer their best practical advice on style, entertaining, travel, healthy eating and more. Personal tips for women living with RMS are incorporated into all of the blogs to ensure their relevance and meaning for those facing an RMS diagnosis.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.
In a mid-morning trade, State Street Corp (NYSE:STT)‘s shares plunge -0.48% to $79.53.
State Street Global Advisors (SSGA), the asset management business of State Street Corporation (STT), today introduced their “Ten Best Practices for Global DC Plans.” The paper provides insights to help multi-national clients with defined contribution plans (DC) in different countries approach them strategically to attract and retain talent and produce better retirement outcomes for employees.
The “Ten Best Practices for Global DC Plans” fall into four categories:
- Define a global vision and related aims and align benefits to support those aims.
- Build efficient governance structures to minimize risk and ensure that plans in different countries support the overall aims.
- Weigh the pros and cons of centralizing investment and other functions to achieve operational and cost efficiencies.
- Improve plans’ effectiveness for employees.
State Street Corporation provides a range of financial products and services to institutional investors worldwide. The company offers investment servicing products and services, counting custody; product- and participant-level accounting; daily pricing and administration; master trust and master custody; record-keeping; cash administration; foreign exchange, brokerage, and other trading services; securities finance; deposit and short-term investment facilities; loans and lease financing; investment manager and alternative investment manager operations outsourcing; and performance, risk, and compliance analytics.
PPG Industries, Inc. (NYSE:PPG), during its Friday’s current trading session -0.29% loss and closed at $117.47.
PPG Industries (PPG) held a meeting for securities analysts in Cabo San Lucas, Mexico. The meeting comprised of presentations by Michael McGarry, PPG president and chief operating officer; and Marcos Achar Levy, PPG vice president, architectural coatings, Latin America, and chief executive officer, PPG-Comex.
During the meeting, PPG reviewed details of PPG-Comex Mexican operations, offered information about the growth of the Mexican economy and PPG-Comex, and toured PPG-Comex concessionaire locations. The company indicated during the meeting it anticipates cost synergies associated with the Comex acquisition to be $45 million to $50 million by the end of 2016, up from the company’s previous guidance of $30 million to $40 million.
PPG also issued new acquisition-related revenue synergy targets for the PPG-Comex acquisition. The company anticipates to generate $40 million to $50 million in revenue within two years from sales of legacy PPG products through the PPG-Comex distribution network. PPG set a separate revenue target of $60 million to $70 million within five years for incremental coatings sales in Central America. PPG had formerly issued no incremental revenue guidance regardingComex.
PPG Industries, Inc. manufactures and distributes coatings, specialty materials, and glass products. The company’s Performance Coatings segment provides coatings products for automotive and commercial transport/fleet repair and refurbishing; light industrial and specialty coatings for signs; sealants, coatings, maintenance cleaners, and transparencies for commercial, military, regional jet and general aviation aircraft, and transparent armor for specialty applications; and chemical administration services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
